Skip to main content

Primary menu

About
- About
- Funding and Support
Team
- Current Team
- Previous Trainees
Research
- What We Do
- All Publications
News
Opportunities
Training Modules
For Patients
- Get Involved
- More Resources

Erythrocyte sedimentation rate, rather than C-reactive protein, may be the preferred biomarker for hidradenitis suppurativa.

Gibson RS, Porter ML, Kimball AB. Erythrocyte sedimentation rate, rather than C-reactive protein, may be the preferred biomarker for hidradenitis suppurativa.. JAAD international. 2022;8:47-48.

See also: HS Publications

Publisher's Version

Last updated on 07/11/2024
PubMed

Recent Publications

Hidradenitis suppurativa: new insights into disease mechanisms and an evolving treatment landscape.
Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled study.
Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial.
Real-World Findings on the Characteristics and Treatment Exposures of Patients with Hidradenitis Suppurativa from US Claims Data.
Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials.
Efficacy and Safety of Risankizumab for the Treatment of Hidradenitis Suppurativa: A Phase 2, Randomized, Placebo-Controlled Trial.

CLEARS

Twitter

Beth Israel Deaconess Medical Center

Secondary menu

Team
Research

Powered byOpenScholar^®Admin Login